Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Datamonitor attended the Jefferies 2012 Global Healthcare Conference held in London over November 14–15, 2012.
This analysis review covers the key highlights of the conference:
Product-specific and overall company updates for: Aegerion, Cubist, Lundbeck, ImmunoGen, Medivation, Novo Nordisk, NPS
The status of late-stage agents such as Roche’s Perjeta (pertuzumab) for breast cancer, Novo Nordisk’s Tresiba (insulin degludec) and Ryzodeg (insulin degludec + insulin aspart) for type 2 diabetes, ImmunoGen’s trastuzumab emtansine (TDM1) for breast cancer, Rigel’s fostamatinib for rheumatoid arthritis, Aegerion’s lopidomide for homozygous familial hypercholesterolemia, NPS Pharmaceuticals’ Gattex (teduglutide) for short bowel syndrome and Natpara (recombinant human parathyroid hormone [1-84]) for the treatment of adult hypoparathyroidism, Cubist’s ceftolozane/tazobactam for complicated urinary tract infections and complicated intra-abdominal infections, and United Therapeutics’ implantable infusion.
Download our White Paper for the full analyst review.
This analysis review covers the key highlights of the conference:
Product-specific and overall company updates for: Aegerion, Cubist, Lundbeck, ImmunoGen, Medivation, Novo Nordisk, NPS
Download our White Paper for the full analyst review.
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
